Who
Kimberly Manhard
Director
Company insider
Files Form 4 as: Director, Inhibrx Biosciences; Director, Inhibrx; EVP, Drug Development, Heron Therapeutics; SVP, Regulatory & Dev Ops, Ardea Biosciences, Inc./DE.
In numbers
- Trades disclosed
- 256
- Buys
- 1
- Sells
- 55
- Bought
- $140K
- Sold
- $7.1M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 21 Dec 2006
- Last trade
- 15 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 15 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $53K500 at $105.05 | filing |
| 15 Sep 2026filed 15 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $53K500 at $105.05 | filing |
| 14 Sep 2026filed 15 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $55K500 at $110.26 | filing |
| 14 Sep 2026filed 15 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $55K500 at $110.26 | filing |
| 11 Sep 2026filed 15 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $56K500 at $111.78 | filing |
| 11 Sep 2026filed 15 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $56K500 at $111.78 | filing |
| 9 Sep 2026filed 10 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $58K500 at $115.80 | filing |
| 9 Sep 2026filed 10 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $58K500 at $115.80 | filing |
| 8 Sep 2026filed 10 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $58K500 at $115.14 | filing |
| 8 Sep 2026filed 10 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Sold | $58K500 at $115.14 | filing |
| 3 Jun 2026filed 18 Sep 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 18 Sep 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 28 May 2025filed 29 May 2025 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 28 Aug 2024filed 30 Aug 2024 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $140K10,000 at $13.98 | filing |
| 30 May 2024filed 30 May 2024 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 30 May 2024filed 30 May 2024 | Inhibrxoption or derivative | SEC FORM 4 Code D | —3,500 | filing |
| 30 May 2024filed 30 May 2024 | Inhibrxoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 30 May 2024filed 30 May 2024 | Inhibrxoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK)INBX · themarketsdaily.com · 25 Oct 2026Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)INBX · tickerreport.com · 23 Oct 2026Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) CEO Acquires $848,982.40 in StockINBX · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Kimberly Manhard; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.